Why the study?
Inflammation plays an essential role in cardiovascular disease pathogenesis, and this review aimed to evaluate colchicine's efficacy, safety, and therapeutic role in CVD management.
Does colchicine reduce major adverse cardiovascular events and mortality in patients with cardiovascular diseases?
Does colchicine reduce major adverse cardiovascular events and mortality in patients with cardiovascular diseases?
Colchicine reduces inflammatory biomarkers in CVD patients, but its impact on hard clinical outcomes like MACE and mortality remains uncertain based on this meta-analysis.
No takes yet. Share an insight, caveat, or question.
Colchicine shows no MACE or mortality benefit; challenges routine use in CVD and leaves net clinical impact open.
Azani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: